ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,099.96
1.02%
Dow Jones
38,239.66
0.40%
US Dollar vs MXN
17.1601
0.00%
Brent Oil
88.165
0.00%
Bitcoin
63,816.19
0.64%
Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Vivos Therapeutics Inc (VVOS)

  7. Vivos Therapeutics Inc (VVOS) Noticias

VVOS Vivos Therapeutics Inc

2.51
0.05 (2.03%)
26 Abr 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Vivos Therapeutics Inc VVOS NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
Upgrade Icon
0.05 2.03% 2.51 15:39:42
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
2.50 2.48 2.61 2.59 2.46
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
09/4/202406:30GLOBEVivos Therapeutics’ Flagship CARE Oral Medical Devices..
28/3/202415:05GLOBEVivos Therapeutics Reports Fourth Quarter and Full Year 2023..
28/3/202406:30GLOBEVivos Therapeutics Schedules Release of Fourth Quarter and..
15/2/202407:55EDGAR2Form 8-K - Current report
15/2/202407:00GLOBEVivos Therapeutics Announces Exercise of Warrants for..
14/2/202416:42EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
06/2/202406:30GLOBEVivos Therapeutics Highlights Significant Favorable Market..
08/1/202406:30GLOBEVivos Therapeutics Sees Positive Preliminary Metrics..
11/12/202306:30GLOBEVivos Therapeutics Presents Groundbreaking Event:..
03/12/202323:15EDGAR2Form EFFECT - Notice of Effectiveness
01/12/202315:12EDGAR2Form 424B1 - Prospectus [Rule 424(b)(1)]
30/11/202315:05EDGAR2Form 8-K - Current report
30/11/202315:03EDGAR2Form S-1/A - General form for registration of securities..
29/11/202306:30GLOBEVivos Therapeutics Receives First Ever FDA 510(k) Clearance..
22/11/202315:46EDGAR2Form S-1 - General form for registration of securities under..
14/11/202315:05GLOBEVivos Therapeutics Reports Third Quarter 2023 Financial..
09/11/202315:30GLOBEVivos Therapeutics Schedules Release of Third Quarter 2023..
03/11/202316:00EDGAR2Form 424B3 - Prospectus [Rule 424(b)(3)]
02/11/202316:10EDGAR2Form 8-K - Current report
02/11/202316:00GLOBEVivos Therapeutics Closes $4 Million Private Placement
31/10/202307:00GLOBEVivos Therapeutics Announces Pricing of $4 Million Private..
27/10/202315:15EDGAR2Form 8-K - Current report
26/10/202306:30GLOBEVivos Therapeutics Announces Reverse Stock Split
24/10/202306:30GLOBEVivos Therapeutics Signs Nationwide Distribution Agreement..
11/10/202306:30GLOBEVivos Therapeutics to Begin Clinical Trial at Stanford..
05/10/202306:30GLOBEVivos Therapeutics Announces Strategic Collaboration in the..
04/10/202314:55APSBiotech Soars On New Agreements
04/10/202306:30GLOBEVivos Therapeutics Executes Strategic Agreements with Ormco..
02/10/202306:30GLOBENew York Times Best-Selling Author James Nestor to Headline..
25/9/202308:00EDGAR2Form 8-K - Current report
21/9/202316:10EDGAR2Form 8-K - Current report
14/9/202315:38EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
06/9/202316:26EDGAR2Form DEFA14A - Additional definitive proxy soliciting..
28/8/202308:00EDGAR2Form DEF 14A - Other definitive proxy statements
21/8/202308:00EDGAR2Form 8-K - Current report
16/8/202315:45EDGAR2Form PRE 14A - Other preliminary proxy statements
16/8/202315:30EDGAR2Form 8-K - Current report
16/8/202315:16EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
16/8/202315:05GLOBEVivos Therapeutics Reports Second Quarter 2023 Financial..
16/8/202306:30GLOBEVivos Therapeutics Reschedules Second Quarter 2023 Financial..
14/8/202316:06GLOBEVivos Therapeutics to Reschedule Second Quarter 2023..
10/8/202319:31GLOBEVivos Therapeutics Schedules Release of Second Quarter 2023..
08/6/202315:05GLOBEVivos Therapeutics Reports First Quarter 2023 Financial..
06/6/202315:30GLOBEVivos Therapeutics Schedules Release of First Quarter..
09/5/202306:30GLOBEVivos Therapeutics Announces Additional Strategic..
01/5/202306:30GLOBEClinical Study Shows 92% of Patients Report Resolution of..

Su Consulta Reciente

NASDAQ
VVOS
Vivos Therapeutics
Delayed Upgrade Clock
ADVFN Logo

México
Empresa
Negocios
Popular
Obtener la aplicación

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados